Today's News | Note: News feeds may no longer be available for the articles on this page.

Santarus: FDA sets action date on heartburn drug 6:38 AM 6/23/2009
MarketWatch - USA
Santarus Inc said the US FDA will act in December 2009 on Schering-Plough HealthCare Products' new-drug application to market an over-the-counter version of Zegerid for heartburn. ...

Andromeda says Teva to market diabetes treatment 5:00 AM 6/22/2009
Reuters - USA
Andromeda Biotech said Teva Pharmaceutical Industries exercised its option to complete a $13.5 million investment to market Andromeda's treatment DiaPep277 in advanced phase III clinical trials for Type I diabetes. ...

Merck to test stimuvax cancer drug in Phase III 4:03 AM 6/22/2009
Reuters - USA
Merck KGaA and US biotech firm Oncothyreon moved their experimental cancer vaccine Stimuvax into the final phase of testing against advanced inoperable breast cancer. ...

Obama lauds pharmaceutical deal 9:00 PM 6/20/2009
The Hill - Washington,DC,USA
Drug companies pledge to help close the Medicare gap between $2,700 and $5,100 that seniors pay themselves. ...

Forest pneumonia drug achieves goal in 2 trials 2:00 PM 6/19/2009
Reuters - USA
Forest Laboratories said its experimental antibiotic drug ceftaroline was well tolerated and met its primary goal of similar effectiveness and high clinical cure rates compared with ceftriaxone in patients with moderate to severe community-acquired bacterial pneumonia requiring hospitalization. ...

Experimental Cephalon cancer drug shows no increased benefit 10:05 AM 6/19/2009
Bizjournals.com - Charlotte,NC,USA
Cephalon's experimental leukemia drug lestaurtinib showed no increased benefit when compared to patients receiving chemotherapy alone for relapsed acute myelogenous leukemia with a genetic mutation involving a FLT3 receptor. ...

Medicines Co. gets new approval for clotting drug 7:15 AM 6/19/2009
Forbes - NY,USA
The Medicines Co said the US FDA granted new marketing exclusivity to the company's anti-clotting agent Angiomax. FDA will not approve generic versions of the drug before September 2010. ...

FDA Approves a Novel Novartis Drug 3:54 AM 6/19/2009
Wall Street Journal - USA
The US FDA approved the sale of Novartis' Ilaris to treat a rare genetic disorder affecting only a few thousand people. It shows Novartis' focus on the genetic triggers that cause disease. ...

Biotech Set to Dominate Drug Industry Growth 8:16 AM 6/18/2009
Seeking Alpha - New York,NY,USA
The cancer antibody drug Avastin is set to be the industry’s top-selling drug in 2014 with revenues over $9 billion. Assuming Lipitor’s crown after the cholesterol-lowering drug goes off patent shows the increasing dominance of biotechnology. ...

China Set to Grant Final Approval for First IPO Since September 4:40 AM 6/18/2009
Bloomberg - USA
Guilin Sanjin Pharmaceutical and Shenzhen Salubris Pharmaceuticals may be among the nation’s first initial public offerings since September. ...

Savient Pharm Rises On Krystexxa Panel Recommendation 12:06 PM 6/17/2009
Wall Street Journal - USA
Savient Pharmaceuticals jumped more than 35% after a US FDA panel backed approval of Krystexxa meant to treat severe gout. ...

Top 6 drugs tipped to be biotech products by 2014 10:39 AM 6/17/2009
Reuters - USA
Biotech drugs to dominate 2014 blockbusters lead by Avastin, Humira, Rituxan, Enbrel, Lantus, and Herceptin. Biotech will account for 50 pct of top 100 drugs. ...

Covidien buys US rights to opioid pain drug 8:22 AM 6/17/2009
Reuters - USA
Covidien Plc has acquired US rights to an experimental opioid pain drug from privately held Neuromed Pharmaceuticals. ...

Molecular Insight Pharmaceuticals Is Surging On Clinical Data 7:42 AM 6/17/2009
RTT News - Williamsville,NY,USA
Molecular Insight Pharmaceuticals presented clinical data on Trofex in development for diagnosis and staging of prostate cancer. Trofex is a radiolabeled small-molecule molecular imaging pharmaceutical. ...

Watson to Acquire Arrow Group for $1.75 Billion 6:13 AM 6/17/2009
Bloomberg - USA
Watson Pharmaceuticals has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion. Watson described Arrow as a fast growing generic pharmaceutical company with $647 million in 2008 revenues. ...

<- Day Earlier | Today's News